Creatine Safety, Tolerability, and Efficacy in Huntington's Disease: CREST-E This is a competing renewal application to complete the ongoing CREST-E clinical trial, which has advanced to Phase III from NCCAM sponsored preclinical and early phase research. CREST-E is an international, multi-center, randomized, double-blind, placebo-controlled, parallel group study involving 650 subjects with Huntington's disease (HD) to assess the efficacy and long-term safety of creatine monohydrate. A companion application is also submitted by Giovanni Schifitto, MD, from the University of Rochester entitled "Creatine Safety and Efficacy in HD: Coordination and Statistical Center" encompassing site coordination, data management, drug supply, study monitoring, and biostatistics. HD is a dominantly inherited, fatal, neurodegenerative disorder, which no treatment has been demonstrated to slow. About 30,000 Americans have clinical HD, and an additional 150,000 are genetically at risk of developing it. Neurodegeneration in HD involves impaired energy production and oxidative damage. Creatine restores ATP from ADP and evidence from HD mice and prior human studies suggest that doses of up to 40 grams daily may slow the course of HD. The primary hypothesis of CREST-E is that creatine will slow the progressive functional decline in early HD as measured by the annualized rate of change in the UHDRS Total Functional Capacity scale. Secondary measures include changes in motor and cognitive scores and long- term safety and tolerability. Exploratory measures include additional clinical outcomes;cognitive and quality of life measures;and putative biomarkers of disease activity and progression. The study was designed to assess the potential for creatine to achieve a clinically meaningful 20% slowing or better. About 64% of subjects have been enrolled, significant safety concerns have not emerged, and the study has been modified to incorporate variable periods of participation to insure completion of all clinical activity by January of 2016. This project is consistent with the NCCAM mission of exploring CAM therapies with scientifically rigorous studies. If the study is positive it would be a breakthrough in HD research that would change HD clinical care and would spur research into similar compounds for a host of related neurodegenerative diseases. Additionally, the study will provide critical information on the long- term safety of high dose creatine which is widely used among healthy athletes and patients with a variety of neurodegenerative disorders and other diseases.
High doses of the nutritional supplement creatine, which reverses brain energy depletion, is a leading candidate neuroprotective treatment for Huntington's disease (HD), a devastating orphan neurogenetic disease that no treatment has yet been able to slow. CREST-E, a definitive international multicenter randomized controlled phase III efficacy study sponsored by NIH/NCCAM is designed to determine whether high dose creatine can slow the course of early HD and this application is seeking to complete the study. If successful, creatine will be the first treatment to slow the course of HD, which will profoundly affect the treatment of HD worldwide.
|Santiago, Jose A; Scherzer, Clemens R; Potashkin, Judith A (2014) Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease. PLoS One 9:e109042|
|Kim, Jinho; Amante, Daniel J; Moody, Jennifer P et al. (2010) Reduced creatine kinase as a central and peripheral biomarker in Huntington's disease. Biochim Biophys Acta 1802:673-81|
|Iverson, D J; Gronseth, G S; Reger, M A et al. (2010) Practice parameter update: evaluation and management of driving risk in dementia: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 74:1316-24|
|Mainero, Caterina; Benner, T; Radding, A et al. (2009) In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI. Neurology 73:941-8|
|Rosas, H Diana; Salat, David H; Lee, Stephanie Y et al. (2008) Complexity and heterogeneity: what drives the ever-changing brain in Huntington's disease? Ann N Y Acad Sci 1147:196-205|
|Hersch, Steven M; Rosas, H Diana (2008) Neuroprotection for Huntington's disease: ready, set, slow. Neurotherapeutics 5:226-36|
|Rosas, H Diana; Salat, David H; Lee, Stephanie Y et al. (2008) Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain 131:1057-68|
|Klein, Autumn M; Ferrante, Robert J (2007) The neuroprotective role of creatine. Subcell Biochem 46:205-43|
|Fox, Jonathan H; Kama, Jibrin A; Lieberman, Gregory et al. (2007) Mechanisms of copper ion mediated Huntington's disease progression. PLoS One 2:e334|
|Kazantsev, Aleksey G; Hersch, Steven M (2007) Drug targeting of dysregulated transcription in Huntington's disease. Prog Neurobiol 83:249-59|
Showing the most recent 10 out of 11 publications